BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23150090)

  • 1. [Radiotherapy in the treatment of advanced and recurrent prostate cancer].
    Böhmer D
    Urologe A; 2012 Dec; 51(12):1759-69; quiz 1770-1. PubMed ID: 23150090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
    Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
    Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy.
    Strom TJ; Wilder RB; Fernandez DC; Mellon EA; Saini AS; Hunt DC; Biagioli MC
    Brachytherapy; 2014; 13(2):123-7. PubMed ID: 24269146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer.
    Åström L; Grusell E; Sandin F; Turesson I; Holmberg L
    Radiother Oncol; 2018 Apr; 127(1):81-87. PubMed ID: 29496280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic overview of radiation therapy effects in prostate cancer.
    Nilsson S; Norlén BJ; Widmark A
    Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate.
    Myers MA; Hagan MP; Todor D; Gilbert L; Mukhopadhyay N; Randolf J; Heimiller J; Anscher MS
    Brachytherapy; 2012; 11(4):292-8. PubMed ID: 22464911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
    Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
    Tharp M; Hardacre M; Bennett R; Jones WT; Stuhldreher D; Vaught J
    Brachytherapy; 2008; 7(3):231-6. PubMed ID: 18579446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Curative radiotherapy of localized prostate cancer. Treatment methods and results].
    Schwarz R
    Urologe A; 2003 Sep; 42(9):1212-20. PubMed ID: 14504754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.
    Löser A; Beyer B; Carl CO; Löser B; Nagaraj Y; Frenzel T; Petersen C; Krüll A; Graefen M; Schwarz R
    Strahlenther Onkol; 2019 May; 195(5):374-382. PubMed ID: 30390115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
    Maenhout M; Peters M; van Vulpen M; Moerland MA; Meijer RP; van den Bosch MAAJ; Nguyen PL; Frank SJ; van der Voort van Zyp JRN
    Technol Cancer Res Treat; 2017 Dec; 16(6):1194-1201. PubMed ID: 29333958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
    Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
    Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
    Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
    Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reirradiation of paraaortic lymph node metastasis by brachytherapy with hyaluronate injection via paravertebral approach: With DVH comparison to IMRT.
    Kishi K; Sonomura T; Shirai S; Noda Y; Sato M; Ikushima H; Oh RJ
    Brachytherapy; 2013; 12(1):8-13. PubMed ID: 22209390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
    Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
    Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.